| Year |
Citation |
Score |
| 2020 |
Chen R, Yu M. Tailored optimal post-treatment surveillance for cancer recurrence. Biometrics. PMID 32712953 DOI: 10.1111/Biom.13341 |
0.348 |
|
| 2020 |
Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, Dang LH, Geynisman DM, Walling R, Alter RS, Kassar M, Wang J, Gupta S, Davis N, Picus J, ... ... Yu M, et al. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1903091. PMID 32271672 DOI: 10.1200/Jco.19.03091 |
0.363 |
|
| 2020 |
Phadke S, Yu M, Miller K, Shah A, Danciu O, Wisinski K. Abstract OT2-06-02: Phase 2 trial with safety-run in of gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive HER2 negative breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Ot2-06-02 |
0.366 |
|
| 2020 |
Witek ME, Harari PM, Burr A, Chandereng T, Yu M, Kimple RJ, Avey G. A Pilot Study of Intra-Treatment MRI/PET to Define Favorable and Unfavorable Radiographic Signatures of Patients with p16-Positive Oropharynx Cancer International Journal of Radiation Oncology Biology Physics. 106: 1148-1149. DOI: 10.1016/J.Ijrobp.2019.11.221 |
0.304 |
|
| 2019 |
Yi Y, Ye T, Yu M, Shao J. Cox Regression with Survival-Time-Dependent Missing Covariate Values. Biometrics. PMID 31549744 DOI: 10.1111/Biom.13155 |
0.304 |
|
| 2019 |
Witt JS, Jagodinsky JC, Liu Y, Yadav P, Kuczmarska-Haas A, Yu M, Maloney JD, Ritter MA, Bassetti MF, Baschnagel AM. Cardiac Toxicity in Operable Esophageal Cancer Patients Treated With or Without Chemoradiation. American Journal of Clinical Oncology. PMID 31313677 DOI: 10.1097/Coc.0000000000000573 |
0.307 |
|
| 2019 |
Zhao SG, Yu M, Spratt DE, Chang SL, Feng FY, Kim MM, Speers CW, Carlson BL, Mladek AC, Lawrence TS, Sarkaria JN, Wahl DR. Xenograft-based platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. Neuro-Oncology. PMID 31121035 DOI: 10.1093/Neuonc/Noz090 |
0.343 |
|
| 2019 |
Galsky MD, Pal SK, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, Dang LH, Geynisman DM, Walling R, Alter RS, Robin EL, Wang J, Gupta S, Chism DD, ... ... Yu M, et al. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182. Journal of Clinical Oncology. 37: 4504-4504. DOI: 10.1200/Jco.2019.37.15_Suppl.4504 |
0.353 |
|
| 2018 |
Kratz JD, Uboha NV, Lubner SJ, Mulkerin DL, Clipson L, Yi Y, Yu M, Matkowskyj KA, LoConte NK, Deming DA. Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 1442-1450. PMID 30545991 DOI: 10.6004/Jnccn.2018.7074 |
0.319 |
|
| 2018 |
Huling J, Yu M, O'Malley AJ. Instrumental Variable Based Estimation Under the Semiparametric Accelerated Failure Time Model. Biometrics. PMID 30357822 DOI: 10.1111/Biom.12985 |
0.304 |
|
| 2018 |
Ye T, Yu M. A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect. Biometrics. PMID 29992543 DOI: 10.1111/Biom.12916 |
0.314 |
|
| 2018 |
Schumacher JR, Neuman HB, Chang GJ, Kozower BD, Edge SB, Yu M, Vanness DJ, Si Y, Jacobs EA, Francescatti AB, Spears PA, Havlena J, Adesoye T, McKellar D, Winchester D, et al. A National Study of the Use of Asymptomatic Systemic Imaging for Surveillance Following Breast Cancer Treatment (AFT-01). Annals of Surgical Oncology. PMID 29777402 DOI: 10.1245/S10434-018-6496-4 |
0.307 |
|
| 2018 |
Neuman HB, Schumacher JR, Francescatti AB, Adesoye T, Edge SB, Vanness DJ, Yu M, McKellar D, Winchester DP, Greenberg CC. Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017755389. PMID 29384721 DOI: 10.1200/Jco.2017.75.5389 |
0.341 |
|
| 2018 |
Witt JS, Jagodinsky JC, Liu Y, Yadav P, Kuczmarska-Haas A, Maloney JD, Yu M, Ritter MA, Bassetti MF, Baschnagel AM. Predictors of Cardiac Toxicity in Operable Esophageal Cancer Patients Treated with or Without Chemoradiation International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.07.451 |
0.312 |
|
| 2018 |
Bruce JY, Harmon G, Woo K, Yu M, Kiltz J, Witek ME, Harari PM, Kimple RJ. Methadone Use During Concurrent Chemoradiation in Patients With Head and Neck Cancer International Journal of Radiation Oncology Biology Physics. 100: 1403. DOI: 10.1016/J.Ijrobp.2017.12.247 |
0.311 |
|
| 2017 |
Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, et al. Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. European Urology. PMID 29248319 DOI: 10.1016/J.Eururo.2017.12.001 |
0.332 |
|
| 2017 |
Ko HC, Harari PM, Chen S, Wieland AM, Yu M, Baschnagel AM, Kimple RJ, Witek ME. Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx. Jama Otolaryngology-- Head & Neck Surgery. PMID 29049434 DOI: 10.1001/Jamaoto.2017.1756 |
0.345 |
|
| 2017 |
Bakoyannis G, Yu M, Yiannoutsos CT. Semiparametric regression on cumulative incidence function with interval-censored competing risks data. Statistics in Medicine. PMID 28608412 DOI: 10.1002/Sim.7350 |
0.3 |
|
| 2017 |
Schumacher JR, Neuman HB, Zhang Y, Yu M, Vanness DJ, Si Y, Burnside ES, Ruddy KJ, Partridge AH, Schrag D, Edge SB, Jacobs EA, Havlena J, Francescatti AB, Spears P, et al. Asymptomatic distant recurrence detection and survival in early stage breast cancer: A nationally representative study. Journal of Clinical Oncology. 35: 6520-6520. DOI: 10.1200/Jco.2017.35.15_Suppl.6520 |
0.328 |
|
| 2017 |
Ko HC, Chen S, Wieland A, Yu M, Baschnagel A, Brower J, McCulloch T, Hartig G, Harari P, Witek M. OC-006: Outcomes of head and neck cancer with N3 nodal disease: a review of the National Cancer Data Base Radiotherapy and Oncology. 122: 6-7. DOI: 10.1016/S0167-8140(17)30163-9 |
0.311 |
|
| 2016 |
Brower JV, Chen S, Bassetti MF, Yu M, Harari PM, Ritter MA, Baschnagel AM. Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012. International Journal of Radiation Oncology, Biology, Physics. 96: 985-993. PMID 27869098 DOI: 10.1016/J.Ijrobp.2016.08.016 |
0.327 |
|
| 2016 |
Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, et al. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. The Lancet. Oncology. PMID 27743920 DOI: 10.1016/S1470-2045(16)30491-0 |
0.328 |
|
| 2016 |
Brower JV, Amini A, Hullett CR, Wojcieszynski AP, Bassetti M, Witek ME, Chen S, Yu M, Baschnagel AM. Dose-Escalated Radiation Therapy Is Associated With Improved Survival in Patients With Stage III Non-Small Cell Lung Cancer: Analysis of the National Cancer Data Base. International Journal of Radiation Oncology, Biology, Physics. 96: S198-S199. PMID 27675769 DOI: 10.1016/J.Ijrobp.2016.06.495 |
0.352 |
|
| 2016 |
Brower JV, Amini A, Chen S, Hullett CR, Kimple RJ, Wojcieszynski AP, Bassetti M, Witek ME, Yu M, Harari PM, Baschnagel AM. Improved survival with dose escalated radiotherapy in Stage III non-small cell lung cancer: Analysis of the National Cancer Data Base. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27502703 DOI: 10.1093/Annonc/Mdw276 |
0.339 |
|
| 2016 |
Neuman HB, Schumacher JR, Francescatti AB, Adesoye T, Edge SB, Yu M, McKellar D, Winchester DP, Greenberg CC. Risk of synchronous distant recurrence at time of local-regional recurrence in stage II and III breast cancer patients. Journal of Clinical Oncology. 34: 6576-6576. DOI: 10.1200/Jco.2016.34.15_Suppl.6576 |
0.328 |
|
| 2016 |
Esbona K, Saha S, Yi Y, Yu M, Wisinski K, Wilke LG, Keely PJ. Abstract 3927: The presence of COX-2 and tumor-associated macrophages as a prognostic marker for invasive breast carcinoma patients Cancer Research. 76: 3927-3927. DOI: 10.1158/1538-7445.Am2016-3927 |
0.314 |
|
| 2016 |
Bossi A, Dearnaley D, McKenzie M, Baskin-Bey E, Tyler R, Tombal B, Freedland SJ, I RM,II, Widmark A, Dicker AP, Wiegel T, Shore N, Smith M, Yu M, Kheoh T, et al. ATLAS : A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw372.52 |
0.32 |
|
| 2014 |
Li Q, Wang S, Huang CC, Yu M, Shao J. Meta-analysis based variable selection for gene expression data. Biometrics. 70: 872-80. PMID 25196635 DOI: 10.1111/Biom.12213 |
0.49 |
|
| 2014 |
Wang L, Zhao Z, Meyer MB, Saha S, Yu M, Guo A, Wisinski KB, Huang W, Cai W, Pike JW, Yuan M, Ahlquist P, Xu W. CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis. Cancer Cell. 25: 21-36. PMID 24434208 DOI: 10.1016/J.Ccr.2013.12.007 |
0.309 |
|
| 2013 |
Becerra CR, Hanna N, McCollum AD, Becharm N, Timmerman RD, DiMaio M, Kesler KA, Yu M, Yan T, Choy H. A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GE junction carcinomas: Hoosier Oncology Group G05-92. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 1425-9. PMID 24084441 DOI: 10.1097/Jto.0B013E3182A46C3B |
0.352 |
|
| 2013 |
Lin Y, Yu M, Wang S, Chappell R, Imperiale TF. Advanced colorectal neoplasia risk stratification by penalized logistic regression. Statistical Methods in Medical Research. PMID 23907780 DOI: 10.1177/0962280213497432 |
0.3 |
|
| 2013 |
Mina LA, Yu M, Johnson C, Burkhardt C, Miller KD, Zon R. A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109. Investigational New Drugs. 31: 1307-10. PMID 23812905 DOI: 10.1007/S10637-013-9976-1 |
0.337 |
|
| 2013 |
Fisher WI, Johnson AK, Elkins GR, Otte JL, Burns DS, Yu M, Carpenter JS. Risk factors, pathophysiology, and treatment of hot flashes in cancer. Ca: a Cancer Journal For Clinicians. 63: 167-92. PMID 23355109 DOI: 10.3322/Caac.21171 |
0.327 |
|
| 2013 |
Galsky MD, Hahn NM, Powles T, Hellerstedt BA, Lerner SP, Gardner TA, Yu M, O'Rourke M, Vogelzang NJ, Kocs D, McKenney SA, Melnyk AM, Hutson TE, Rauch M, Wang Y, et al. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clinical Genitourinary Cancer. 11: 175-81. PMID 23228446 DOI: 10.1016/J.Clgc.2012.10.001 |
0.336 |
|
| 2013 |
Riggs H, Jalal SI, Baghdadi TA, Bhatia S, McClean J, Johnson C, Yu M, Taber D, Harb W, Hanna N. Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77. Clinical Lung Cancer. 14: 224-9. PMID 23102811 DOI: 10.1016/J.Cllc.2012.09.004 |
0.359 |
|
| 2012 |
Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 4416-26. PMID 23150697 DOI: 10.1200/Jco.2012.42.4358 |
0.333 |
|
| 2012 |
Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, Croop JM, Vik TA, Denne SC, Parada LF, Hingtgen CM, Walsh LE, Yu M, Pradhan KR, Edwards-Brown MK, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. The Lancet. Oncology. 13: 1218-24. PMID 23099009 DOI: 10.1016/S1470-2045(12)70414-X |
0.341 |
|
| 2012 |
Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. Journal of the National Cancer Institute. 104: 1837-40. PMID 23093559 DOI: 10.1093/Jnci/Djs435 |
0.331 |
|
| 2012 |
Chiorean EG, Sanghani S, Schiel MA, Yu M, Burns M, Tong Y, Hinkle DT, Coleman N, Robb B, LeBlanc J, Clark R, Bufill J, Curie C, Loehrer PJ, Cardenes H. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. Cancer Chemotherapy and Pharmacology. 70: 25-32. PMID 22610353 DOI: 10.1007/S00280-012-1883-1 |
0.34 |
|
| 2012 |
Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. The Oncologist. 17: 13. PMID 22210086 DOI: 10.1634/Theoncologist.2011-0253 |
0.349 |
|
| 2012 |
Jalal SI, Riggs HD, Melnyk A, Richards D, Agarwala A, Neubauer M, Ansari R, Govindan R, Bruetman D, Fisher W, Breen T, Johnson CS, Yu M, Einhorn L, Hanna N. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 1730-8. PMID 22156624 DOI: 10.1093/Annonc/Mdr565 |
0.337 |
|
| 2012 |
Seng SM, Liu Z, Chiu S, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao C, Yu M, Hahn NM, Oh WK, Galsky MD. Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis. Journal of Clinical Oncology. 30: e21016-e21016. DOI: 10.1200/Jco.2012.30.15_Suppl.E21016 |
0.359 |
|
| 2012 |
Yu M, Bardia A, Wittner B, Stott S, Smas M, Ting D, Isakoff S, Ciciliano J, Wells M, Shah A, Concannon K, Sequist L, Brachtel E, Sgroi D, Baselga J, et al. Abstract P2-01-14: circulating tumor cells in breast cancer exhibit dynamic changes in epithelial and mesenchymal cell composition Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P2-01-14 |
0.318 |
|
| 2011 |
Feliciano JL, Hanna NH, Fakiris A, Yu M, Dugan WM, McClean J, Bufill JA, Bhatia S, Patel JD. A phase II study of concurrent pemetrexed and radiation for poor-risk stage III non-small cell lung cancer (NSCLC): Hoosier Oncology Group LUN08-129. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e17529. PMID 28020179 DOI: 10.1200/Jco.2011.29.15_Suppl.E17529 |
0.333 |
|
| 2011 |
Khawaja MR, Zyromski N, Yu M, Cardenes HR, Schmidt CM, Sandusky G, Howard TJ, Chiorean EG. Effect of body mass index (BMI) on outcomes after surgical resection and adjuvant therapy for pancreatic cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 185. PMID 27985349 DOI: 10.1200/Jco.2011.29.4_Suppl.185 |
0.324 |
|
| 2011 |
Cardenes HR, Moore AM, Johnson CS, Yu M, Helft P, Chiorean EG, Vinson J, Howard TJ, Stephens AW, Tai DF, Loehrer PJ. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study. American Journal of Clinical Oncology. 34: 460-5. PMID 20881474 DOI: 10.1097/Coc.0B013E3181E9C103 |
0.332 |
|
| 2010 |
Jalal S, Bedano P, Einhorn L, Bhatia S, Ansari R, Bechar N, Koneru K, Govindan R, Wu J, Yu M, Schneider B, Hanna N. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 2008-11. PMID 21102263 DOI: 10.1097/Jto.0B013E3181F77B6E |
0.354 |
|
| 2010 |
Barriger RB, Fakiris AJ, Hanna N, Yu M, Mantravadi P, McGarry RC. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. International Journal of Radiation Oncology, Biology, Physics. 78: 1381-6. PMID 20231061 DOI: 10.1016/J.Ijrobp.2009.09.030 |
0.326 |
|
| 2010 |
Cardenes HR, Sanghani S, Burns M, Robb B, Hinkle DT, Johnson CS, Yu M, Currie CR, Loehrer PJ, Chiorean EG. Phase II trial of neoadjuvant capecitabine (C) with irinotecan (I) followed by capecitabine-based chemoradiotherapy (CRT) for patients (pts) with locally advanced rectal cancer (LARC): HOG GI03-53. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E14026 |
0.317 |
|
| 2010 |
Cardenes H, Sanghani S, Burns M, Robb B, Hinkle D, Johnson C, Yu M, Currie C, Loehrer P, Chiorean E. Phase II Trial of Neoadjuvant Capecitabine (Cp) with Irinotecan (Ir) followed by Capecitabine-based Chemoradiotherapy (CRT) for Patients (pts) with Locally Advanced Rectal Cancer (LARC): A Hoosier Oncology Group Study International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.160 |
0.336 |
|
| 2009 |
Al Baghdadi T, Hanna N, Bhatia S, McClean J, Johnson C, Yu M, Taber D, Harb W. Erlotinib and bevacizumab in chemotherapy-naive performance status 2 patients with advanced non-small cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e19082. PMID 27962191 DOI: 10.1200/Jco.2009.27.15_Suppl.E19082 |
0.351 |
|
| 2009 |
Jalal S, Waterhouse D, Edelman MJ, Nattam S, Ansari R, Koneru K, Clark R, Richards A, Wu J, Yu M, Bottema B, White A, Hanna N. Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 1420-4. PMID 19701110 DOI: 10.1097/Jto.0B013E3181B624Ae |
0.336 |
|
| 2009 |
Hahn NM, Zon RT, Yu M, Ademuyiwa FO, Jones T, Dugan W, Whalen C, Shanmugam R, Skaar T, Sweeney CJ. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67 Annals of Oncology. 20: 1971-1976. PMID 19605506 DOI: 10.1093/Annonc/Mdp244 |
0.35 |
|
| 2009 |
Jalal S, Ansari R, Govindan R, Bhatia S, Bruetman D, Fisher W, Masters G, White A, Stover D, Yu M, Hanna N. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 93-6. PMID 19096313 DOI: 10.1097/Jto.0B013E31818De1E6 |
0.362 |
|
| 2008 |
Krop IE, Miller KD, Zon RT, Isakoff S, Schneider CJ, Yu M, Johnson C, Vaughn LG, Shonukan OO, Sledge GW. A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane-containing regimen: HOG BRE05-97. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1004. PMID 27951391 DOI: 10.1200/Jco.2008.26.15_Suppl.1004 |
0.316 |
|
| 2008 |
Hahn NM, Zon RT, Jones T, Ademuyiwa F, Dugan WM, Whalen C, Yu M, Shanmugam R, Skaar T, Sweeney CJ. A multicenter phase II study of pemetrexed as second-line chemotherapy for the treatment of hormone refractory prostate cancer (HRPC); Hoosier Oncology Group GU-0367. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 16019. PMID 27947271 DOI: 10.1200/Jco.2008.26.15_Suppl.16019 |
0.33 |
|
| 2008 |
Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn LH, Hanna N. Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 374-9. PMID 18379355 DOI: 10.1097/Jto.0B013E3181693869 |
0.353 |
|
| 2008 |
Chiorean EG, Porter JM, Foster AE, Al Omari AS, Yoder CA, Fife KL, Strother RM, Murry DJ, Yu M, Jones DR, Sweeney CJ. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1131-7. PMID 18281547 DOI: 10.1158/1078-0432.Ccr-07-0437 |
0.305 |
|
| 2008 |
Yu M, Taylor JMG, Sandler HM. Individual prediction in prostate cancer studies using a joint longitudinal survival-cure model Journal of the American Statistical Association. 103: 178-187. DOI: 10.1198/016214507000000400 |
0.34 |
|
| 2007 |
Jalal SI, Waterhouse D, Edelman M, Nattam S, Ansari R, Koneru K, Yu M, Shen J, Breen T, Hanna N. Pemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): A phase I-IIa dose-ranging study from the Hoosier Oncology Group Journal of Clinical Oncology. 25: 7698-7698. DOI: 10.1200/Jco.2007.25.18_Suppl.7698 |
0.305 |
|
| 2006 |
Hammoud ZT, Kesler KA, Ferguson MK, Battafarrano RJ, Bhogaraju A, Hanna N, Govindan R, Mauer AA, Yu M, Einhorn LH. Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer. Diseases of the Esophagus. 19: 69-72. PMID 16643172 DOI: 10.1111/J.1442-2050.2006.00542.X |
0.37 |
|
| 2006 |
Moore AM, Einhorn LH, Estes D, Govindan R, Axelson J, Vinson J, Breen TE, Yu M, Hanna NH. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer (Amsterdam, Netherlands). 52: 93-7. PMID 16488055 DOI: 10.1016/J.Lungcan.2005.12.002 |
0.377 |
|
| 2006 |
Navari RM, Einhorn LH, Loehrer PJ, Passik SD, Vinson J, McClean J, Chowhan N, Hanna N, Calley C, Yu M. A phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting (CINV) Journal of Clinical Oncology. 24: 8608-8608. DOI: 10.1200/Jco.2006.24.18_Suppl.8608 |
0.317 |
|
| 2005 |
Taylor JM, Yu M, Sandler HM. Individualized predictions of disease progression following radiation therapy for prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 816-25. PMID 15681526 DOI: 10.1200/Jco.2005.12.156 |
0.331 |
|
| 2005 |
Moore AM, Estes D, Govindan R, Vinson J, Calley C, Yu M, Einhorn L, Hanna N. A phase II trial of gefitinib in patients with chemosensitive and chemorefractory relapsed neuroendocrine cancers. A Hoosier Oncology Group Trial Journal of Clinical Oncology. 23: 7160-7160. DOI: 10.1200/Jco.2005.23.16_Suppl.7160 |
0.327 |
|
| 2002 |
Dash A, Sanda MG, Yu M, Taylor JM, Fecko A, Rubin MA. Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on Cancer. Urology. 60: 276-80. PMID 12137826 DOI: 10.1016/S0090-4295(02)01727-2 |
0.305 |
|
| Show low-probability matches. |